Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II Study of AZD5863 in Advanced or Metastatic CLDN18.2-positive Solid Tumors
2023-504139-42-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Nov 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 8
01
Overview
Phase 2, open-label trial of HBM7022 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, esophageal adenocarcinoma (EAC) and 1 more (2 arms), sponsored by AstraZeneca. Primary endpoints: Incidence of AEs, AESIs, DLTs and SAEs (Dose Escalation), AEs leading to discontinuation of AZD5863 (Dose Escalation) and 5 more. Planned start Nov 2023; status: authorised.
02
Drugs
HBM7022
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2023-504139-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504139-42-00.